Article Text
Statistics from Altmetric.com
Review ofLyttle M, Rainford NEA, Gamble C, et al. Levetiracetam vs phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393:2125–34andDalziel SR, Borland ML, Furyk J, et al. Levetiracetam vs phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2019;393:2135–45.
ConSEPT trial: Levetiracetam is not superior to phenytoin in the management of convulsive status epilepticus
Design: The 'Convulsive Status Epilepticus Paediatric Trial' (ConSEPT) was an open label randomised controlled trial.
Allocation: 1:1 computer-generated block randomisation, stratified by site and age.
Setting: 13 emergency departments (ED) in New Zealand and Australia (8 tertiary paediatric EDs).
Patients: 234 children aged 3 months to 16 years presenting with convulsive status epilepticus. Patients had already received two doses of benzodiazepines.
Intervention: Levetiracetam 40 mg/kg over 5 min intravenous or intraosseous.
Comparison: Phenytoin 20 mg/kg over 20 min intravenous/intraosseous.
The participant was assessed 5 min after the infusion had finished; if seizure activity was present, the other study medication was also given. A video was used to independently assess the time of seizure …
Footnotes
Twitter @becksDrD
Contributors RAD wrote the abstract and commentary.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.